Clinical Trials Directory

Trials / Completed

CompletedNCT05644691

Impact of the Daily Use of Emollient on Corticosteroids Consumption in Patients With Atopic Dermatitis

Impact of the Daily Use of the Tested Emollient on Corticosteroids Consumption in Patients Minimum 3 Years Old With Atopic Dermatitis (SCORAD 20-30) Versus Their Usual Emollient

Status
Completed
Phase
Study type
Observational
Enrollment
119 (actual)
Sponsor
Cosmetique Active International · Industry
Sex
All
Age
3 Years
Healthy volunteers
Accepted

Summary

This study aims at assessing the reduction of consumption of corticosteroids (same mid-potent corticosteroids for all patients) afforded by the use of a specific emollient in comparison to the usual one in subjects suffering from atopic dermatitis.

Detailed description

The study is conducted in compliance, as closely as possible, with the current version of the world medical association declaration of Helsinki, local regulations based on International Council on Harmonisation (ICH) guidelines for Good Clinical Practice. The primary objective of this study is to compare the tested emollient and the usual emollient through the weight of used dermocorticosteroid. The weight of used dermocorticosteroid is compared at the end of the study by a Student t-test (or a non parametric Wilcoxon test depending on the data distribution). The following hypotheses are used for the estimation of the sample size calculation: * Power (1 - β) = 80% * Two-sided significance level (α) = 5% * Expected inter-group difference = 0.6g * Standard deviation = 1.4g. Statistical analyses is performed with SAS® version 9.4 or higher (SAS institute, North Carolina, USA). Continuous variables are summarized as number of observations, mean, standard deviation, standard error, median, minimum and maximum (95% confidence interval will be provided if necessary). For categorical variables, subject counts and percentages will be provided. Analyses use 2-sided tests at the 5% significance level, except the normality tested at the threshold of 1% (Shapiro-Wilk test).

Conditions

Interventions

TypeNameDescription
OTHERLipikar Baume AP+Mapplication of Lipikar Baume AP+M twice daily for 3 months in parallel with the corticosteroid treatment
OTHERUsual emollientapplication of the usual emollient twice daily for 3 months in parallel with the corticosteroid treatment

Timeline

Start date
2020-10-14
Primary completion
2021-07-14
Completion
2021-07-14
First posted
2022-12-09
Last updated
2022-12-09

Locations

1 site across 1 country: Slovakia

Source: ClinicalTrials.gov record NCT05644691. Inclusion in this directory is not an endorsement.